Pfizer Inc. $PFE Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.6% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 3,978,354 shares of the biopharmaceutical company’s stock after purchasing an additional 446,069 shares during the period. Russell Investments Group Ltd.’s holdings in Pfizer were worth $96,425,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Westbourne Investments Inc. purchased a new stake in shares of Pfizer during the 1st quarter worth approximately $2,411,000. Bourne Lent Asset Management Inc. boosted its stake in shares of Pfizer by 90.8% during the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after buying an additional 18,200 shares during the period. Strs Ohio purchased a new position in shares of Pfizer in the 1st quarter valued at approximately $49,968,000. IFM Investors Pty Ltd grew its position in Pfizer by 3.8% in the 2nd quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock valued at $27,322,000 after buying an additional 41,263 shares during the last quarter. Finally, Intrua Financial LLC boosted its holdings in shares of Pfizer by 17.4% in the first quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company’s stock valued at $1,986,000 after acquiring an additional 11,643 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PFE. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Morgan Stanley cut their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Finally, Guggenheim increased their price objective on shares of Pfizer from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $28.39.

Pfizer Price Performance

Shares of PFE stock opened at $25.72 on Thursday. The firm has a fifty day simple moving average of $24.94 and a 200-day simple moving average of $24.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $146.21 billion, a PE ratio of 13.68, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.